DESIGN OF BETA CELL LYMPHOMA-2 (BCL-2) RECEPTOR ANTAGONISTS AS CHEMOTHERAPEUTIC AGENTS
- At: AbuDhabi (United Arab Emirates) (2019)
- Type: Poster
- Poster code: POS-DDD-008
- By: SHOEMAKE, Claire (University of Malta, Pharmacy, Malta)
- Co-author(s): Yvonne Savona Ventura: Pharmacy, University of Malta, Msida, Malta
Claire Shoemake: Pharmacy, University of Malta, Msida, Malta
The Beta Cell Lymphoma-2 (BCL-2) receptor is a prosurvival protein. It is consequently a target in the design of molecules capable of restoring cells' to perform apoptosis. Navitoclax and venetoclax are BCL-2 antagonists, but are associated with thrombocytopaenic side-effects.
A virtual screening approach was adopted. Bioactive.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.